CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies.
about
Combination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia.Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survivalOptimizing Stem Cells Mobilization Strategies to Ameliorate Patient Outcomes: A Review of Guide- lines and Recommendations.Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT).Day 100 Peripheral Blood Absolute Lymphocyte/Monocyte Ratio and Survival in Classical Hodgkin's Lymphoma Postautologous Peripheral Blood Hematopoietic Stem Cell Transplantation.Higher doses of CD34+ progenitors are associated with improved overall survival without increasing GVHD in reduced intensity conditioning allogeneic transplant recipients with clinically advanced disease.Bone marrow donor-related variables associated with harvest outcome in HLA-haploidentical transplantation with postinfusion cyclophosphamide.
P2860
Q34348102-70AF7702-14B8-4F2E-BDE9-4FDD181EE308Q35769347-B503BD38-7FEB-4C02-9F88-708BAAC6B80AQ37682128-CA1C53BD-0071-4C47-BFED-F74807A45789Q39488956-6CD2EC3D-CACB-41C0-93CF-B357F02D45D7Q40752311-4AE8515F-18A0-4CA3-9DF1-880FF36E7DC3Q50986967-1FFB5BD5-CDCF-406B-B8C2-AF89391B2A39Q53163203-0D11BE8A-9D49-44BC-A20D-EAA49768420D
P2860
CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
CD34+ cell dose and establishm ...... for hematologic malignancies.
@en
CD34+ cell dose and establishm ...... for hematologic malignancies.
@nl
type
label
CD34+ cell dose and establishm ...... for hematologic malignancies.
@en
CD34+ cell dose and establishm ...... for hematologic malignancies.
@nl
prefLabel
CD34+ cell dose and establishm ...... for hematologic malignancies.
@en
CD34+ cell dose and establishm ...... for hematologic malignancies.
@nl
P2093
P2860
P356
P1476
CD34+ cell dose and establishm ...... for hematologic malignancies.
@en
P2093
D A Gastineau
D J Inwards
I N Micallef
L F Porrata
M A Elliott
M R Litzow
P B Johnston
S G Holtan
S M Ansell
P2860
P2888
P304
P356
10.1038/BMT.2010.49
P407
P577
2010-03-08T00:00:00Z
P5875
P6179
1027551857